Albert von der Assen

Publications by Year

Research Areas

Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Estrogen and related hormone effects

Most-Cited Works

• → Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer(2019)49 cited
• → Partial PTEN deletion is linked to poor prognosis in breast cancer(2015)44 cited
• → p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer(2016)44 cited
• → Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial(2019)23 cited
• → A shift from membranous and stromal syndecan‐1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer(2019)21 cited
• → Acute and Long-Term Toxicity after Planned Intraoperative Boost and Whole Breast Irradiation in High-Risk Patients with Breast Cancer—Results from the Targeted Intraoperative Radiotherapy Boost Quality Registry (TARGIT BQR)(2024)3 cited
• → 5201 POSTER The EXpand Study – Effect of Zoledronic Acid on Prevention of Bone Loss, During Extended Adjuvant Therapy With Letrozole in Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer Compared to Letrozole Alone(2011)2 cited
• → Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry(2023)2 cited
• → Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study(2018)2 cited
• → Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.(2014)2 cited